Current Report Filing (8-k)
June 13 2017 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2017
PSIVIDA CORP.
(Exact
Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
000-51122
|
|
26-2774444
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
480 Pleasant Street
Watertown, MA 02472
(Address of Principal Executive Offices) (Zip Code)
(617)
926-5000
(Registrants Telephone Number, Including Area Code)
Not applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On June 13, 2017, pSivida Corp. issued a press release announcing that the
Companys second Phase 3 clinical trial of Durasert three-year treatment for posterior segment uveitis achieved the trials primary efficacy endpoint. A copy of the press release making such announcement is furnished as
Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press release dated June 13, 2017
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
PSIVIDA CORP.
|
|
|
|
|
Date: June 13, 2017
|
|
|
|
By:
|
|
/s/ Nancy Lurker
|
|
|
|
|
Name:
|
|
Nancy Lurker
|
|
|
|
|
Title:
|
|
President and CEO
|
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Sep 2023 to Sep 2024